TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma

TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma

Bibliographic Details
Main Authors: Caihua Xu, MD, Dapeng Li, MD, Weiming Duan, MD, Min Tao, PhD
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:JTO Clinical and Research Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320300394

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320300394

Similar Items